JP6783224B2 - 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 - Google Patents

肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 Download PDF

Info

Publication number
JP6783224B2
JP6783224B2 JP2017503798A JP2017503798A JP6783224B2 JP 6783224 B2 JP6783224 B2 JP 6783224B2 JP 2017503798 A JP2017503798 A JP 2017503798A JP 2017503798 A JP2017503798 A JP 2017503798A JP 6783224 B2 JP6783224 B2 JP 6783224B2
Authority
JP
Japan
Prior art keywords
methyl
phenyl
pharmaceutical composition
group
pat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017503798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512841A5 (cg-RX-API-DMAC7.html
JP2017512841A (ja
Inventor
バカ、ジェフリー、エイ．
ブラウン、デニス、エム．
ステイノ、アンネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2017512841A publication Critical patent/JP2017512841A/ja
Publication of JP2017512841A5 publication Critical patent/JP2017512841A5/ja
Application granted granted Critical
Publication of JP6783224B2 publication Critical patent/JP6783224B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
JP2017503798A 2014-04-04 2015-04-06 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 Expired - Fee Related JP6783224B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461975587P 2014-04-04 2014-04-04
US61/975,587 2014-04-04
US201462062246P 2014-10-10 2014-10-10
US62/062,246 2014-10-10
PCT/US2015/024462 WO2015154064A2 (en) 2014-04-04 2015-04-06 Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer

Publications (3)

Publication Number Publication Date
JP2017512841A JP2017512841A (ja) 2017-05-25
JP2017512841A5 JP2017512841A5 (cg-RX-API-DMAC7.html) 2018-05-17
JP6783224B2 true JP6783224B2 (ja) 2020-11-11

Family

ID=54241453

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017503798A Expired - Fee Related JP6783224B2 (ja) 2014-04-04 2015-04-06 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
JP2018511343A Pending JP2018515613A (ja) 2014-04-04 2016-05-12 癌を治療するための白金含有抗腫瘍剤とジアンヒドロガラクチトールの類縁体又は誘導体の組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018511343A Pending JP2018515613A (ja) 2014-04-04 2016-05-12 癌を治療するための白金含有抗腫瘍剤とジアンヒドロガラクチトールの類縁体又は誘導体の組み合わせ

Country Status (13)

Country Link
US (2) US11541027B2 (cg-RX-API-DMAC7.html)
EP (2) EP3125920B1 (cg-RX-API-DMAC7.html)
JP (2) JP6783224B2 (cg-RX-API-DMAC7.html)
KR (2) KR102359214B1 (cg-RX-API-DMAC7.html)
CN (1) CN106659765B (cg-RX-API-DMAC7.html)
AU (2) AU2015240465B2 (cg-RX-API-DMAC7.html)
CA (1) CA2946538A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016002514A1 (cg-RX-API-DMAC7.html)
IL (1) IL248189B (cg-RX-API-DMAC7.html)
MX (1) MX385778B (cg-RX-API-DMAC7.html)
SG (1) SG11201608303QA (cg-RX-API-DMAC7.html)
TW (1) TW201713326A (cg-RX-API-DMAC7.html)
WO (2) WO2015154064A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
MX342017B (es) 2010-03-26 2016-09-09 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
JP6285923B2 (ja) 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
EP3552628A1 (en) 2012-09-07 2019-10-16 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11123426B2 (en) 2014-06-11 2021-09-21 The Trustees Of Dartmouth College Use of vista agonists and antagonists to suppress or enhance humoral immunity
CN115414480A (zh) * 2014-11-10 2022-12-02 德玛医药 结合放射用于治疗非小细胞肺癌和多形性胶质母细胞瘤的二去水卫矛醇
MX2017007136A (es) 2014-12-05 2017-12-04 Immunext Inc Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
CN114805576A (zh) 2015-06-24 2022-07-29 詹森药业有限公司 抗vista抗体和片段
US20190091195A1 (en) * 2015-09-10 2019-03-28 Del Mar Pharmaceuticals Use of dianhydrogalactitol and derivatives thereof in the treatment of glioblastoma, lung cancer, and ovarian cancer
US11784303B2 (en) 2015-09-22 2023-10-10 Ii-Vi Delaware, Inc. Immobilized chalcogen and use thereof in a rechargeable battery
US11588149B2 (en) 2015-09-22 2023-02-21 Ii-Vi Delaware, Inc. Immobilized selenium in a porous carbon with the presence of oxygen, a method of making, and uses of immobilized selenium in a rechargeable battery
US12159994B2 (en) 2015-09-22 2024-12-03 Ii-Vi Delaware, Inc. Immobilized selenium, a method of making, and uses of immobilized selenium in a rechargeable battery
US12155058B2 (en) 2015-09-22 2024-11-26 Ii-Vi Delaware, Inc. Immobilized chalcogen comprising a chalcogen element, an electrically conductive material, and hydrophilic membrane gate and use thereof in a rechargeable battery
US11446274B2 (en) 2015-10-28 2022-09-20 Del Mar Pharmaceuticals (Bc) Ltd. Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
PE20190115A1 (es) 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
US11870059B2 (en) 2017-02-16 2024-01-09 Consejo Superior De Investigaciones Cientificas (Csic) Immobilized selenium in a porous carbon with the presence of oxygen, a method of making, and uses of immobilized selenium in a rechargeable battery
EP3589282A4 (en) * 2017-02-28 2020-09-02 Del Mar Pharmaceuticals (BC) Ltd. USE OF DIANHYDROGALACTITOL OR ANALOGUES AND DERIVATIVES IN COMBINATION WITH A P53 MODULATOR OR PARP INHIBITOR
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN106947821B (zh) * 2017-04-11 2020-06-30 成都望路医药技术有限公司 用于诊治结肠腺癌的生物标志物
CN107447027A (zh) * 2017-09-13 2017-12-08 赵小刚 检测egfr基因g873r位点突变的试剂盒
CN107540746B (zh) * 2017-10-17 2022-07-12 北京格根生物科技有限公司 一种抗血管内皮生长因子抗体及与铁调素的融合蛋白
CN112996534B (zh) * 2018-08-07 2025-11-18 因斯瑞拜奥有限公司 结合间变性淋巴瘤激酶抑制剂进行egf/egfr通路抑制的方法和组合物
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
CN109517776A (zh) * 2018-11-16 2019-03-26 河北科技师范学院 一种肠炎沙门菌icdA基因缺失株及其应用
CN110927387B (zh) * 2019-11-08 2022-05-20 江苏大学 一种brca2蛋白酶联免疫双抗夹心试剂盒及其应用
JP2023511135A (ja) * 2020-01-21 2023-03-16 ザ・ペン・ステイト・リサーチ・ファウンデイション 神経損傷の治療及び／または創傷治癒の促進のための方法及び材料
CN111228307B (zh) * 2020-02-16 2020-12-29 中山大学附属第五医院 巨噬细胞在保护血管屏障中的应用以及卵巢癌腹水的预防、抑制和治疗
WO2022061001A1 (en) * 2020-09-16 2022-03-24 Splash Pharmaceuticals, Inc. Methods for patent selection and treatment of cancer
CN113896721B (zh) * 2020-07-06 2024-09-20 华东师范大学 具有肿瘤靶向的烟酰胺磷酸核糖转移酶抑制剂
KR102560912B1 (ko) * 2020-08-26 2023-07-28 한양대학교 에리카산학협력단 엑소좀을 유효성분으로 포함하는 폐암 치료, 예방 또는 전이 억제용 약학적 조성물
KR102199001B1 (ko) * 2020-09-25 2021-01-06 이화여자대학교 산학협력단 간암 진단을 위한 신규 바이오마커
CN112575005A (zh) * 2021-01-04 2021-03-30 昆明理工大学 一种提高烟草重金属镉胁迫抗性和降低镉富集的方法
JP2023140319A (ja) 2022-03-22 2023-10-04 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン

Family Cites Families (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853221A (en) 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5294430A (en) 1988-09-12 1994-03-15 University Of Rochester Use of dithiocarbamates to treat myelosuppression
US5035878A (en) 1988-09-12 1991-07-30 University Of Rochester Use of dithiocarbamates to counteract myelosuppression
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5597798A (en) 1990-03-05 1997-01-28 The Regents Of The University Of California Taxol and epidermal growth factor used to enhance treatment of ovarian cancer
ES2187500T3 (es) 1991-02-21 2003-06-16 Smithkline Beecham Corp Uso de topotecano en el tratamiento del carcinoma pulmonar no de celulas pequeñas.
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
US5795870A (en) 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
EP0758549A4 (en) 1994-04-26 1997-07-02 Nobuhiro Narita MEDICAL COMPOSITION AS A MEDICINE FOR NON-SMALL CELL CANCER
US6011069A (en) 1995-12-26 2000-01-04 Nisshin Flour Milling Co., Ltd. Multidrug resistance inhibitors
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
CA2293674A1 (en) 1997-06-04 1998-12-10 Egbert Bakker A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
US6335156B1 (en) 1997-12-18 2002-01-01 The Johns Hopkins University School Of Medicine 14-3-3σ arrests the cell cycle
CA2319495A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
ATE315392T1 (de) 1998-07-09 2006-02-15 Francis A Nardella Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
WO2001007084A1 (en) 1999-07-23 2001-02-01 Regents Of The University Of California Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US20020037328A1 (en) * 2000-06-01 2002-03-28 Brown Dennis M. Hexitol compositions and uses thereof
GB0014820D0 (en) 2000-06-16 2000-08-09 Medical Res Council Methods and materials relating to plasmid vectors
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
US7619005B2 (en) 2000-11-01 2009-11-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans with Multiple Sclerosis
WO2003000012A2 (en) 2001-06-21 2003-01-03 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
EP2138575B8 (en) 2002-02-20 2013-07-24 Mersana Therapeutics, Inc. Conjugates comprising a biodegradable polymer and uses therefor
US7910314B2 (en) 2002-03-01 2011-03-22 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
CA2480176A1 (en) 2002-04-11 2003-10-23 Zymogenetics, Inc. Use of interleukin-24 to treat ovarian cancer
JP2005529101A (ja) 2002-04-11 2005-09-29 ザイモジェネティクス インコーポレイティッド 卵巣癌を治療するためのインターロイキン−１９の使用法
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
WO2004064748A2 (en) 2003-01-21 2004-08-05 Trustees Of Dartmouth College Compositions and methods for treatment of ovarian cancer
WO2004085505A2 (en) 2003-03-24 2004-10-07 Sequoia Pharmaceuticals, Inc. Long acting biologically active conjugates
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
JP4851933B2 (ja) 2003-04-11 2012-01-11 ピーティーシー セラピューティクス，インコーポレーテッド １，２，４−オキサジアゾール安息香酸化合物ならびにナンセンス抑制及び疾患の治療のためのその使用
KR20060088102A (ko) 2003-09-04 2006-08-03 아벤티스 파마슈티칼스 인크. 폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ)의 억제제로서의치환된 인돌
JP2007507524A (ja) 2003-10-02 2007-03-29 セフアロン・インコーポレーテツド インドール誘導体
HUP0303313A2 (hu) 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
AU2004289539C1 (en) 2003-11-14 2012-06-07 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
DK1725528T3 (da) 2004-03-11 2013-09-02 4Sc Ag Sulfonylpyrroler som hdac-inhibitorer
WO2005099824A1 (en) 2004-03-30 2005-10-27 Synta Pharmaceuticals, Corp. 1-glyoxylamide indolizines for treating lung and ovarian cancer
WO2005098446A2 (en) 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
WO2006001967A2 (en) 2004-05-25 2006-01-05 Sloan-Kettering Institute For Cancer Research Migrastatin analogs in the treatment of cancer
ATE498613T1 (de) 2004-06-30 2011-03-15 Janssen Pharmaceutica Nv Chinazolinonderivate als parp-hemmer
ES2440990T5 (es) 2004-07-22 2022-10-25 Univ Erasmus Med Ct Rotterdam Moléculas de unión
CA2580719C (en) 2004-08-20 2013-10-22 Buck Institute For Age Research Small molecules that replace or agonize p53 function
CA2579810C (en) 2004-09-17 2012-01-24 Eisai R&D Management Co., Ltd. Stable pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
AU2005316652B2 (en) 2004-12-15 2009-07-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinations of therapeutic agents for treating cancer
MX2007008771A (es) 2005-01-19 2007-09-11 Mgi Gp Inc Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp.
WO2006081158A2 (en) 2005-01-25 2006-08-03 The Regents Of The University Of California Predictive and therapeutic markers in overian cancer
EP1702989A1 (en) 2005-03-16 2006-09-20 Fundacion para la Investigacion Clinica y Molecular del Cancer de Pulmon Method of predicting the clinical response to cisplatin or carboplatin chemotherapeutic treatment
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
UA95775C2 (uk) 2005-04-26 2011-09-12 Пфайзер Инк. Антитіло, яке специфічно зв'язується з р-кадгерином
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
JP5159616B2 (ja) 2005-06-15 2013-03-06 カーディオム ファーマ コーポレイション アミノシクロヘキシルエーテル化合物の調製のための合成プロセス
EP1910821B1 (en) 2005-06-24 2013-02-20 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
JP2009501235A (ja) * 2005-07-15 2009-01-15 シェーリング コーポレイション 癌処置において有用なキナゾリン誘導体
US8133692B2 (en) 2005-07-20 2012-03-13 University Of South Florida Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するピラゾール化合物
US8124095B2 (en) 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US7507536B2 (en) 2005-10-07 2009-03-24 The Johns Hopkins University Methylation markers for diagnosis and treatment of ovarian cancer
KR20080066039A (ko) 2005-10-19 2008-07-15 추가이 세이야쿠 가부시키가이샤 신규 수용성 프로드러그를 함유하는 췌장암, 난소암 또는 간암의 예방 또는 치료제
US20090099102A1 (en) 2005-10-27 2009-04-16 The Brigham And Women's Hospital, Inc. Ginkgolides in the Treatment and Prevention of Ovarian Cancer
CA2629244C (en) 2005-11-11 2014-08-05 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
DE602006015508D1 (de) 2005-11-16 2010-08-26 Pantarhei Bioscience Bv Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
CA2634468C (en) 2005-12-23 2014-10-07 Ecobiotics Limited Spiroketals
EP1986625B1 (en) 2006-02-10 2012-08-01 Ramot at Tel-Aviv University Ltd. Treatment of ovarian cancer
ES2422890T3 (es) 2006-03-17 2013-09-16 Ambit Biosciences Corporation Compuestos de imidazolotiazol para el tratamiento de enfermedades proliferativas
UA95799C2 (en) 2006-04-26 2011-09-12 Ф. Хоффманн-Ля Рош Аг Pharmaceutical compounds
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
BRPI0711011A2 (pt) 2006-05-18 2011-08-23 Molecular Profiling Institute, Inc. método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
WO2007149907A2 (en) 2006-06-20 2007-12-27 Abbott Laboratories Pyrazoloquinazolinones as parp inhibitors
PL2061765T3 (pl) 2006-09-01 2015-04-30 Senhwa Biosciences Inc Modulatory białkowych kinaz serynowo-treoninowych i PARP
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
CN101678022A (zh) 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
US8168415B2 (en) 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
DK2129396T3 (da) 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antistoffer mod ErbB3 og anvendelser deraf
KR20090115879A (ko) 2007-02-28 2009-11-09 이노텍 파마슈티컬스 코포레이션 인데노이소퀴놀리논 유사체와 이의 이용 방법
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体
US8030060B2 (en) 2007-03-22 2011-10-04 West Virginia University Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
MX2009010828A (es) 2007-04-06 2009-10-29 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de gonadotropina y metodos relacionados con los mismos.
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
JP2008295328A (ja) 2007-05-30 2008-12-11 Fujifilm Corp 卵巣癌の検出方法、及び抑制方法
CN101678019B (zh) 2007-06-08 2016-03-30 詹森药业有限公司 哌啶/哌嗪衍生物
KR20120087885A (ko) 2007-06-29 2012-08-07 안국약품 주식회사 난소암의 예측 마커
US8981131B2 (en) 2007-07-27 2015-03-17 Piramal Enterprises Limited Tricyclic compounds for the treatment of inflammatory disorders
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8309573B2 (en) 2007-08-10 2012-11-13 Mitsubishi Tanabe Pharma Corporation Salt of isoquinoline compound and crystal thereof
CN101802226A (zh) 2007-09-17 2010-08-11 皇家飞利浦电子股份有限公司 分析卵巢癌病症的方法
EP2842956A1 (en) 2007-10-03 2015-03-04 Eisai Inc. PARP inhibitor compounds, compositions and methods of use
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
CN101909630A (zh) 2007-11-02 2010-12-08 新加坡科技研究局 预防和治疗肿瘤的方法和化合物
IL187247A0 (en) 2007-11-08 2008-12-29 Hadasit Med Res Service Novel synthetic analogs of sphingolipids
NZ586123A (en) 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
US20090170842A1 (en) 2007-11-14 2009-07-02 University Of Kansas Brca1-based breast or ovarian cancer prevention agents and methods of use
ES2524787T3 (es) 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
CA2705952C (en) 2007-11-23 2018-05-01 British Columbia Cancer Agency Branch Methods for detecting lung cancer and monitoring treatment response
WO2009075799A2 (en) 2007-12-05 2009-06-18 The Wistar Institute Of Anatomy And Biology Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
US8933212B2 (en) 2007-12-06 2015-01-13 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Use of protease nexin 1 inhibitors to reduce metastasis
US8741889B2 (en) 2008-01-11 2014-06-03 Hoffmann-La Roche Inc Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor
ES2494365T3 (es) 2008-01-30 2014-09-15 Genentech, Inc. Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
US8642347B2 (en) 2008-01-31 2014-02-04 The Brigham And Women's Hospital, Inc. Urinary CA125 peptides as biomarkers of ovarian cancer
JP2011511078A (ja) 2008-02-06 2011-04-07 レアド トヘラペウトイクス，インコーポレーテッド ポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のベンズオキサゾールカルボキサミド阻害剤
JP2011511076A (ja) 2008-02-08 2011-04-07 エイルロン セラピューティクス，インコーポレイテッド 治療用ペプチド模倣大環状分子
WO2009101639A1 (en) 2008-02-14 2009-08-20 Decode Genetics Ehf. Susceptibility variants for lung cancer
TWI441639B (zh) 2008-02-20 2014-06-21 Actelion Pharmaceuticals Ltd 用於治療卵巢癌之包含紫杉醇之組合
FR2928151B1 (fr) 2008-03-03 2010-12-31 Sanofi Aventis Derives platine-carbene n-heterocyclique, leur preparation et leur application en therapeutique
KR101601997B1 (ko) 2008-03-17 2016-03-17 암비트 바이오사이언시즈 코포레이션 Ｒａｆ 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법
WO2009145815A2 (en) 2008-04-01 2009-12-03 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
KR101626136B1 (ko) 2008-04-14 2016-06-03 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 플렉스트린 상동 도메인의 소분자 억제제 및 이의 사용방법
WO2009127619A1 (en) 2008-04-16 2009-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment, the prognostic assessment and the staging of non-small cell lung cancer
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
WO2009137921A1 (en) 2008-05-14 2009-11-19 University Health Network Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
ES2529361T3 (es) 2008-06-11 2015-02-19 Genentech, Inc. Dicarbazoles y métodos de uso
HRP20130045T1 (hr) 2008-07-09 2013-02-28 Rigel Pharmaceuticals, Inc. Premošteni bicikliäśki heteroaril supstituirani triazoli koji su korisni kao axl inhibitori
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
US8338477B2 (en) 2008-07-11 2012-12-25 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
LT2767537T (lt) 2008-08-06 2017-08-10 Medivation Technologies, Inc. Poli(adp-ribozės)polimerazės (parp) dihidropiridoftalazinono inhibitoriai
WO2010017545A2 (en) 2008-08-08 2010-02-11 Synta Pharamceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2732658A1 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
EP2331547B1 (en) 2008-08-22 2014-07-30 Novartis AG Pyrrolopyrimidine compounds as cdk inhibitors
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
KR100961410B1 (ko) 2008-10-14 2010-06-09 (주)네오팜 단백질 키나제 억제제로서 헤테로사이클릭 화합물
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
US8946275B2 (en) 2008-10-21 2015-02-03 Threshold Pharmaceuticals, Inc. Treatment of cancer using hypoxia activated prodrugs
US8946289B2 (en) 2008-11-19 2015-02-03 Duke University Manassatin compounds and methods of making and using the same
HRP20130409T2 (hr) 2008-11-26 2013-11-22 Pfizer Inc. 3-aminociklopentankarboksamidi kao modulatori kemokinskih receptora
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8058075B2 (en) 2008-12-10 2011-11-15 University Of Utah Research Foundation Molecular fluorescence sensor for highly sensitive and selective detection of mercury
EP2380024B1 (en) 2008-12-22 2014-06-11 Roche Diagnostics GmbH Armet as a marker for cancer
BRPI1007358A2 (pt) 2009-01-23 2018-03-06 Takeda Pharmaceutical Company Limited inibidores de poli (adp-ribose) polimerase (parp)
EP2396007A1 (en) 2009-02-10 2011-12-21 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
US8648046B2 (en) 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
EP2401267B1 (en) 2009-02-27 2014-01-15 Ambit Biosciences Corporation Jak kinase modulating quinazoline derivatives and their use in methods
US8969001B2 (en) 2009-03-12 2015-03-03 Rush University Medical Center Materials and methods for predicting recurrence of non-small cell lung cancer
CN101869558A (zh) * 2009-04-22 2010-10-27 北京大学 二乙酰二脱水卫矛醇的抗血管生成及肿瘤转移作用
PT104607B (pt) 2009-05-20 2012-03-23 Univ De Coimbra Derivados triterpenóides úteis como agentes antiproliferativos
ES2679379T3 (es) 2009-06-15 2018-08-24 Nerviano Medical Sciences S.R.L. Derivados de pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
WO2011014681A1 (en) 2009-07-30 2011-02-03 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS
EP2460005A4 (en) 2009-07-31 2012-11-21 Translational Genomics Res Inst METHOD FOR ASSESSING A CANCER PROGRESSION RISK
EP2471791B1 (en) 2009-08-26 2014-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
US20130203861A1 (en) 2009-09-09 2013-08-08 Golden Biotechnology Corporation Methods and compositions for treating ovarian cancer
US20120183546A1 (en) 2009-09-23 2012-07-19 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
KR101449217B1 (ko) 2009-09-28 2014-10-08 에프. 호프만-라 로슈 아게 벤즈옥세핀 ｐｉ3ｋ 억제제 화합물 및 사용 방법
CN102548945A (zh) 2009-10-08 2012-07-04 桑福德-伯纳姆医学研究院 作为抗癌剂的阿朴棉子酚酮衍生物
WO2011042217A1 (en) 2009-10-09 2011-04-14 Oryzon Genomics S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
JP2013517281A (ja) 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッド 化合物及び方法
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
JP5972176B2 (ja) 2010-02-23 2016-08-17 サノフイ 抗アルファ２インテグリン抗体及びそれらの使用
EP2548017A2 (en) 2010-03-15 2013-01-23 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same
WO2011117668A1 (en) 2010-03-22 2011-09-29 Council Of Scientific & Industrial Research Carbazole linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof
CA2797468C (en) 2010-04-27 2018-04-24 Pharma Mar, S.A. Anticancer steroidal lactones unsaturated in position 7 (8)
WO2011138409A1 (en) 2010-05-05 2011-11-10 Universität Bayreuth Combretastatin analogs for use in the treatment of cancer
CN103003424B (zh) 2010-05-18 2015-05-13 株式会社医学生物学研究所 结合转化生长因子α且对Ras基因突变的癌具有增殖抑制活性的抗体
DK2918588T3 (en) 2010-05-20 2017-08-28 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
CN105061438B (zh) 2010-06-23 2017-07-04 韩美科学株式会社 用于抑制酪氨酸激酶活性的稠合嘧啶衍生物
US8962679B2 (en) 2010-07-08 2015-02-24 The Administrators Of The Tulane Educational Fund Daidzein analogs as treatment for cancer
ES2552841T3 (es) 2010-07-12 2015-12-02 Bayer Intellectual Property Gmbh Imidazo[1,2-a]pirimidinas y -piridinas sustituidas
GB201012105D0 (en) 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
US20120171694A1 (en) 2010-07-30 2012-07-05 Vermillion, Inc. Predictive markers and biomarker panels for ovarian cancer
US8987267B2 (en) 2010-08-05 2015-03-24 Temple University—Of the Commonwealth System of Higher Education 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders
EP3246026A3 (en) * 2010-08-18 2018-02-21 Del Mar Pharmaceuticals Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
US8471026B2 (en) 2010-08-26 2013-06-25 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US8975260B2 (en) 2010-09-01 2015-03-10 Genetech, Inc Pyridazinones, method of making, and method of use thereof
WO2012030896A2 (en) 2010-09-01 2012-03-08 Arqule, Inc. Methods for treatment of non-small cell lung cancer
US8980955B2 (en) 2010-09-17 2015-03-17 Indiana University Research And Technology Small molecule inhibitors of replication protein A that also act synergistically with cisplatin
WO2012047570A1 (en) 2010-09-28 2012-04-12 Schering Corporation Fused tricyclic inhibitors of mammalian target of rapamycin
KR101497113B1 (ko) 2010-10-20 2015-03-03 한국생명공학연구원 Ｈｉｆ-1 활성을 저해하는 아릴옥시페녹시아크릴계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
EA201370107A1 (ru) 2010-11-11 2013-11-29 Редкс Фарма Лимитед Производные лекарственных средств
EP2638395A4 (en) 2010-11-12 2016-06-01 Endocyte Inc METHOD FOR TREATING CARCINOMA
AR083916A1 (es) 2010-11-18 2013-04-10 Takeda Pharmaceutical Metodo para tratar el cancer de mama y cancer de ovarios
EP2646430B1 (en) 2010-12-03 2016-09-21 Emory University Chemokine cxcr4 receptor modulators and uses related thereto
US8927560B2 (en) 2010-12-06 2015-01-06 Council Of Scientific & Industrial Research 4-Aza-2, 3-didehydropodophyllotoxin compounds and process for the preparation thereof
MY164910A (en) 2010-12-16 2018-02-15 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
JP5883457B2 (ja) 2010-12-17 2016-03-15 アール リチャードソン，デ チオセミカルバゾン化合物および癌の治療における使用
WO2012096832A2 (en) 2011-01-12 2012-07-19 Crystal Biopharmaceutical Llc Hdac inhibiting derivatives of camptothecin
EP2668190B1 (en) 2011-01-26 2016-08-17 Nerviano Medical Sciences S.r.l. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
US8946409B2 (en) 2011-01-27 2015-02-03 Board Of Regents, The University Of Texas System Polycyclic β lactam derivatives for the treatment of cancer
US8987257B2 (en) 2011-01-31 2015-03-24 Novartis Ag Heterocyclic derivatives
EP2678021A4 (en) 2011-02-24 2015-07-01 Jiangsu Hansoh Pharmaceutical PHOSPHORUS COMPOUNDS AS A PROTEIN KINASE INHIBITOR
CA2828119A1 (en) 2011-02-24 2012-08-30 Vermillion, Inc. Biomarker panels, diagnostic methods and test kits for ovarian cancer
WO2012116328A2 (en) 2011-02-24 2012-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bad phosphorylation determines ovarian cancer chemo-sensitivity and patient survival
ES2951688T3 (es) 2011-02-28 2023-10-24 Epizyme Inc Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos
ES2569185T3 (es) 2011-03-01 2016-05-09 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
EP2908132B8 (en) 2011-03-02 2019-06-12 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
CA2828889A1 (en) 2011-03-04 2012-09-13 New York University Hydrogen bond surrogate macrocycles as modulators of ras
US8748470B2 (en) 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
US20140357605A1 (en) 2012-03-22 2014-12-04 Bristol-Myers Squibb Company Bis(fluoroalkyl)-1,4-benzodiazepinone compounds
WO2012138537A1 (en) 2011-04-01 2012-10-11 Immunogen, Inc. Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer
WO2012138678A1 (en) 2011-04-04 2012-10-11 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
KR101974673B1 (ko) 2011-06-24 2019-05-02 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물
CN105198862B (zh) 2011-07-27 2018-01-23 阿斯利康(瑞典)有限公司 取代的n‑(4‑氟‑2‑甲氧基‑5‑硝基苯基)嘧啶‑2‑胺化合物及其盐
US9499530B2 (en) 2011-08-01 2016-11-22 Hangzhou Minsheng Institutes For Pharma Research Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament
WO2013020062A1 (en) 2011-08-04 2013-02-07 Array Biopharma Inc. Quinazoline compounds as serine/threonine kinase inhibitors
US9045450B2 (en) 2011-08-10 2015-06-02 Zhen Yang Method for chemical synthesis of antrocin and use thereof for suppressing non-small cell lung cancer
DE102011112978A1 (de) 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
JP6053795B2 (ja) 2011-09-19 2016-12-27 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 強力なｈｄａｃ阻害剤としてのラクタムを有する新しいチオ誘導体、及び治療剤としてのその使用
WO2013043255A1 (en) 2011-09-21 2013-03-28 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
AU2012312305B2 (en) 2011-09-22 2016-11-17 Merck Sharp & Dohme Corp. Acyclic cyanoethylpyrazoles as janus kinase inhibitors
EP2771337B1 (en) 2011-09-27 2017-08-02 Novartis AG 3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh
SI2760860T1 (sl) 2011-09-28 2017-04-26 Euro-Celtique S.A. Derivati dušikove gorčice
WO2013053045A1 (en) 2011-10-12 2013-04-18 Beta Pharma Canada Inc. Heterocyclic molecules as apoptosis inducers
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2013062943A1 (en) 2011-10-24 2013-05-02 Glaxosmithkline Intellectual Property Development Limited New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
HK1201733A1 (en) 2011-11-03 2015-09-11 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
CN104024255B (zh) 2011-11-03 2017-01-18 霍夫曼-拉罗奇有限公司 作为btk活性的抑制剂的烷基化哌嗪化合物
CN104185631A (zh) 2011-11-10 2014-12-03 纪念斯隆-凯特琳癌症中心 用2-氨基-4H-萘并[1,2-b]吡喃-3-甲腈治疗卵巢癌
WO2013071001A1 (en) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center Treatment of ovarian cancer with benzylidenebenzohydrazides
BR112014011197A2 (pt) 2011-11-11 2017-04-25 Lilly Co Eli terapia combinada para o câncer ovariano
KR20140097402A (ko) 2011-11-22 2014-08-06 데시페라 파마슈티칼스, 엘엘씨. 항암 및 항증식 활성을 나타내는 피리돈 아미드 및 유사체
WO2013096755A1 (en) 2011-12-21 2013-06-27 New York University Proteolytically resistant hydrogen bond surrogate helices
EP2802586B1 (en) 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
US20150087600A1 (en) 2012-01-19 2015-03-26 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US10201521B2 (en) * 2012-01-20 2019-02-12 Del Mar Pharmaceuticals (Bc) Ltd. Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem and cancer stem cells including glioblastoma multiforme and medulloblastoma
JP6006241B2 (ja) 2012-01-31 2016-10-12 第一三共株式会社 ピリドン誘導体
AR092790A1 (es) 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
MX347772B (es) 2012-03-06 2017-05-12 Cephalon Inc Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak.
US9266828B2 (en) 2012-03-16 2016-02-23 Sanford-Burnham Medical Research Institute Inhibitors of Furin and other pro-protein convertases
ES2641864T3 (es) 2012-03-20 2017-11-14 Novartis Ag Terapia de combinación de un inhibidor de MEK y un inhibidor de IGF1R
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
JP6192708B2 (ja) 2012-03-30 2017-09-06 ライゼン・ファーマシューティカルズ・エスアー Ｃ−ｍｅｔプロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−イミダゾ［４，５−ｂ］ピリジン化合物および３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
US9809858B2 (en) 2012-04-05 2017-11-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. O-glycan pathway ovarian cancer signature
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
MX2014013751A (es) 2012-05-11 2015-08-07 Abbvie Inc Piridazina y derivados de piridina como inhibidores de nampt.
WO2013181462A1 (en) 2012-05-31 2013-12-05 Amgen Inc. Use of amg 900 for the treatment of cancer
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US8980934B2 (en) 2012-06-22 2015-03-17 University Health Network Kinase inhibitors and method of treating cancer with same
BR112014032346A2 (pt) * 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
WO2014009319A1 (en) 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
WO2014078295A1 (en) 2012-11-13 2014-05-22 BoYen Therapeutics, Inc. Gemcitabine prodrugs and uses thereof
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
US8946246B2 (en) 2012-11-16 2015-02-03 New Mexico Technical Research Foundation Synthetic rigidin analogues as anticancer agents, salts, solvates and prodrugs thereof, and method of producing same
MX2015007205A (es) 2012-12-06 2016-03-31 Quanticel Pharmaceuticals Inc Inhibidores de la desmetilasa de histona.
MX373639B (es) 2012-12-20 2020-05-04 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
KR20150100814A (ko) 2012-12-21 2015-09-02 콴티셀 파마슈티컬스, 인크. 히스톤 데메틸라제 억제제
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
PT2956173T (pt) 2013-02-14 2017-06-26 Bristol Myers Squibb Co Compostos de tubulisina, métodos de produção e utilização
US8980879B2 (en) 2013-03-11 2015-03-17 Abbvie Inc. Bromodomain inhibitors
CA2901929A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
WO2014143241A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10413538B2 (en) 2013-05-08 2019-09-17 Bionumerik Pharmaceuticals, Inc. Administration of karenitecin for the treatment of platinum and/or taxane chemotherapy-resistant or -refractory advanced ovarian cancer
US20140371158A1 (en) 2013-06-14 2014-12-18 Georgia Regents University Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway
AU2014100435A4 (en) 2013-06-17 2014-05-29 Macau University Of Science And Technology A novel treatment of Gefitinib-resistant non-small-cell lung cancer
MX2015018038A (es) 2013-07-03 2016-03-16 Hoffmann La Roche Compuestos de heteroaril-piridona y aza-piridona-amida.
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
US20150065526A1 (en) 2013-09-05 2015-03-05 Emory University Overcoming acquired resistance to chemotherapy treatments through suppression of stat3
US8927717B1 (en) 2014-02-14 2015-01-06 National Defense Medical Center Thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof

Also Published As

Publication number Publication date
JP2018515613A (ja) 2018-06-14
KR20220021013A (ko) 2022-02-21
CA2946538A1 (en) 2015-10-08
AU2016262079A1 (en) 2018-01-04
CN106659765A (zh) 2017-05-10
AU2016262079A8 (en) 2018-01-18
KR102456088B1 (ko) 2022-10-19
US20160008316A1 (en) 2016-01-14
TW201713326A (zh) 2017-04-16
US20190269646A9 (en) 2019-09-05
US11541027B2 (en) 2023-01-03
US20180140571A1 (en) 2018-05-24
WO2015154064A2 (en) 2015-10-08
CN106659765B (zh) 2021-08-13
MX385778B (es) 2025-03-18
EP3125920B1 (en) 2020-12-23
MX2016013027A (es) 2017-05-23
IL248189B (en) 2020-05-31
AU2015240465A1 (en) 2016-10-27
CL2016002514A1 (es) 2017-12-15
EP3125920A4 (en) 2018-03-07
AU2015240465B2 (en) 2020-02-27
IL248189A0 (en) 2016-11-30
KR102359214B1 (ko) 2022-02-07
EP3294284A1 (en) 2018-03-21
JP2017512841A (ja) 2017-05-25
SG11201608303QA (en) 2016-11-29
EP3125920A2 (en) 2017-02-08
KR20160132130A (ko) 2016-11-16
WO2016183331A1 (en) 2016-11-17
WO2015154064A3 (en) 2016-01-14
EP3294284A4 (en) 2019-02-20

Similar Documents

Publication Publication Date Title
JP6783224B2 (ja) 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
JP2022088616A (ja) 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法
JP2021004244A (ja) 多形神経膠芽腫及び髄芽腫を含む新生物疾患及び癌幹細胞を処置するためのジアンヒドロガラクチトール及び類似体を含めた置換ヘキシトールの使用
US20160067241A1 (en) Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
CN112472699A (zh) 改善比生群及衍生物的治疗益处的组合方法
JP2022174200A (ja) 医薬組成物
US20190091195A1 (en) Use of dianhydrogalactitol and derivatives thereof in the treatment of glioblastoma, lung cancer, and ovarian cancer
US20180071244A1 (en) Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies
TW201815395A (zh) 二去水半乳糖醇或其衍生物或類似物於治療小兒中樞神經系統惡性病之用途
CN108024987A (zh) 用于治疗癌症的二去水卫矛醇的类似物或衍生物与含铂抗肿瘤药物的组合
CA2985511A1 (en) Combination of analogs or derivatives of dianhydrogalactitol with platinum-containing antineoplastic agents to treat cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200831

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200925

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201021

R150 Certificate of patent or registration of utility model

Ref document number: 6783224

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees